Overall market sentiment has been neutral on Progenity Inc (PROG) stock lately. PROG receives a Neutral rating from InvestorsObserver Stock Sentiment Indicator.
Progenity Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on PROG!
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With PROG Stock Today?
Progenity Inc (PROG) stock is lower by -1.29% while the S&P 500 has risen 0.02% as of 2:34 PM on Monday, Aug 9. PROG is lower by -$0.03 from the previous closing price of $1.94 on volume of 944,073 shares. Over the past year the S&P 500 is higher by 32.05% while PROG is lower by -78.90%. PROG lost -$9.20 per share in the over the last 12 months.
To see InvestorsObserver's Sentiment Score for Progenity Inc click here.
More About Progenity Inc
Progenity Inc is a biotechnology company. It is engaged in developing and commercializing molecular testing products as well as innovating in the field of precision medicine. It utilizes a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics, to molecular testing products and to the development of a suite of investigational ingestible devices and drug and device combinations designed to provide precise diagnostic sampling and drug delivery solutions. The firm generates its revenue from molecular laboratory tests, principally from the sale of Innatal, Preparent, and pathology molecular testing. The company's operations are carried out in the United States.
Click Here to get the full Stock Report for Progenity Inc stock.